1. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation.
- Author
-
Tang OS, Xu J, Cheng L, Lee SW, and Ho PC
- Subjects
- Abortifacient Agents, Nonsteroidal adverse effects, Abortifacient Agents, Nonsteroidal pharmacology, Abortifacient Agents, Steroidal adverse effects, Abortifacient Agents, Steroidal pharmacology, Administration, Oral, Administration, Sublingual, Adult, Drug Synergism, Female, Gestational Age, Humans, Mifepristone adverse effects, Mifepristone pharmacology, Misoprostol adverse effects, Misoprostol pharmacology, Pilot Projects, Pregnancy, Pregnancy Trimester, First, Abortifacient Agents, Nonsteroidal administration & dosage, Abortifacient Agents, Steroidal administration & dosage, Abortion, Induced methods, Mifepristone administration & dosage, Misoprostol administration & dosage
- Abstract
Background: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study., Methods: One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 microg (4 x 200 microg tablets) of sublingual misoprostol., Results: Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively., Conclusions: The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol.
- Published
- 2002
- Full Text
- View/download PDF